Nicola J Mason

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 6

Top Topics

Palliative Care

Mesenchymal Stem Cells

Chronic Lymphocytic Leukemia

Top Venues

Veterinary and comparative oncology

Veterinary pathology

This page only lists publications with an associated author ORCID identifier.

Publications

Sho Yoshimoto, Nicholas Chester, Ailian Xiong, Enrico Radaelli, Hong Wang, Marc Brillantes, Gayathri Gulendran, Patrick Glassman, Don L Siegel, Nicola J Mason
Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors. mAbs 15 (1) (2023)
Matthew J Atherton, Nicola J Mason
Bite-size introduction to canine hematologic malignancies. Blood advances 6 (13) (2022)
Guannan Wang, Ming Wu, Amy C Durham, Nicola J Mason, David B Roth
Canine Oncopanel: A capture-based, NGS platform for evaluating the mutational landscape and detecting putative driver mutations in canine cancers. Veterinary and comparative oncology (2021)
Amy K LeBlanc, Matthew J Atherton, R Timothy Bentley, C Elizabeth Boudreau, Jenna H Burton, Kaitlin M Curran, Steven Dow, Michelle A Giuffrida, Heidi B Kellihan, Nicola J Mason, Michelle L Oblak, Laura Elizabeth Selmic, Kimberly A Selting, Ameet Singh, Sonja Tjostheim, David M Vail, Kristen M Weishaar, Erika P Berger, John H Rossmeisl, Christina Mazcko
Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats. Veterinary and comparative oncology 19 (2) (2021)
Kumudhini Preethi Haran, Alexandra Lockhart, Ailian Xiong, Enrico Radaelli, Patrick J Savickas, Avery Posey, Nicola J Mason
Generation and Validation of an Antibody to Canine CD19 for Diagnostic and Future Therapeutic Purposes. Veterinary pathology 57 (2) (2020)
Matthew J Atherton, Jennifer A Lenz, Nicola J Mason
Sarcomas-A barren immunological wasteland or field of opportunity for immunotherapy? Veterinary and comparative oncology 18 (4) (2020)